pCPA Monthly Trends & Insights – April 2018

May 7, 2018
-

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update

 

The April 30, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are:

  • Seven new drug products have initiated pCPA negotiations, for a total of 46 active negotiations;
  • One negotiation was completed (none closed), for a total of 208 joint completed/closed negotiations; and
  • No new drug products were added to the “No pCPA Negotiations” list, for a total of 58 products for which the pCPA has declined to negotiate – collectively or at the provincial-territorial level.

Negotiation Initiation

  • Seven new drug products have initiated pCPA negotiations since the last update, for a total of 46 active negotiations
Brand Name Generic Name Manufacturer Indication Recommendation/
Notification to Implement Date
Time to Initiation* (days)
Adlyxine Lixisenatide Sanofi-aventis Canada Inc Diabetes mellitus, Type 2 November 23, 2017 143
Ilaris Canakinumab Novartis Pharmaceuticals Systematic juvenile idiopathic arthritis June 17, 2016 N/A
Izba Travoprost Novartis Pharmaceuticals Open angle glaucoma October 25, 2017 172
Renflexis Infliximab Merck Canada Inflammatory Conditions February 20, 2018 54
Rexulti Brexpiprazole Otsuka-Lundbeck schizophrenia November 22, 2017 144
Tresiba Insulin degludec Novo Nordisk Canada Inc. Diabetes mellitus, type 1 and 2 November 20, 2017 146
Viacoram Perindopril arginine/amlodipine Servier Canada Inc. Essential hypertension October 26, 2016 N/A

*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation

Signals Decoded:

Of the 7 files initiating negotiations this month, two had previously been considered and declined by pCPA; Ilaris in January 2017 and Viacoram in July 2017. In addition, the pCPA has initiated negotiations on a third GLP-1 product (Adlyxine) while talks continue on both Trulicity and Victoza. Finally, a couple of negotiations with implications for biosimilars – Renflexis is the second infliximab biosimilar to be negotiated while Tresiba is the first long-acting insulin product to enter that therapeutic space, post-biosimilar entry (Basaglar).

While the chart above considers all files (including pCPA-initiated negotiations) under pCPA management, the chart below focuses on the rate at which pCPA is initiating files coming through the HTA process and into the “pCPA Consideration” phase.

 

Negotiations Completed/Closed

  • One negotiation was completed (none closed) since the last update, for a total of 208 joint completed/closed negotiations.
Brand Name Generic Name Manufacturer Indication Negotiation Initiation Duration *
Kyleena Levonorgestrel Bayer Prevention of pregnancy September, 2017 212 days

*Approximation: Negotiation initiation and completion date assumed to be mid-month for the purposes of the calculation

Files Under pCPA Consideration

In addition to the monthly updates to the pCPA website, MORSE Consulting tracks the number of products “under pCPA Consideration” which have been reviewed by CADTH but have not yet been initiated for negotiation or closed without negotiations.

  • Six new drug products received a CDEC or pERC recommendation or notification to implement in April 2018, for a total of approximately 28 products under pCPA Consideration.
Brand Name Generic Name Manufacturer Indication Final Recommendation/
Notification to Implement
Alecensaro Alectinib Hoffmann-La Roche Limited Locally advanced or metastatic non-small cell lung cancer (second line) Conditional Reimbursement
Bavencio Avelumab EMD Serono – Pfizer Alliance metastatic Merkel Cell Carcinoma Conditional Reimbursement
Vectibix Panitumumab Amgen Canada Inc. Left Sided Metastatic Colorectal Cancer Does not Recommend
Ocrevus Ocrelizumab Hoffman La Roche Primary progressive multiple sclerosis Conditional Reimbursement
MDK-nitisinone Nitisinone MendeliKABS Inc Hereditary tyrosinemia type 1 Conditional Reimbursement
Monoprost Latanoprost Laboratoires Thea Glaucoma and ocular hypertension Conditional Reimbursement

No pCPA Negotiation

  • No new drug products were added to the “No pCPA Negotiations” list, for a total of 58 products for which the pCPA has declined collective or provincial/territorial-level negotiations.

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share